Janssen Biotech, Inc. announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults living with moderate to...
Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has approved Tremfya (guselkumab injection) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
The UK NICE has recommended the use of Tremfya (guselkumab), from Janssen, as a cost-effective treatment for plaque psoriasis for...
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA seeking approval of Tremfya (guselkumab) for treatment of adults with moderately to severely active ulcerative colitis (UC)
If approved, guselkumab will be the first selective IL-23 p19 subunit inhibitor for people in the European Union with active psoriatic arthritis.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced a Network Meta-Analysis (NMA) comparing first-in-class interleukin (IL)-23 inhibitor Tremfya (guselkumab) to all advanced therapies approved for active psoriatic arthritis (PsA using data from 33 Phase III randomized clinical trials (RCTs).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the ECLIPSE study demonstrating that Tremfya (guselkumab) was superior...